Preventing Teratogenicity in women with epilepsy

Kinney, Michael O., Smith, Phil E. M. ORCID: https://orcid.org/0000-0003-4250-2562 and Craig, John J. 2022. Preventing Teratogenicity in women with epilepsy. Seminars in Neurology 42 (05) , pp. 679-692. 10.1055/s-0042-1759579

Preview

PDF - Published Version Download (652kB) | Preview

Abstract

Over the last 50 years there has been a significant increase in our understanding of the issues faced by women with epilepsy, in both planning and undertaking pregnancy. The risks of teratogenicity associated with antiseizure medications have emerged slowly. The major pregnancy registers have substantially contributed to our knowledge about teratogenic risk associated with the commonly used antiseizure medications. However, there are substantial gaps in our knowledge about the potential risks associated with many third-generation drugs. The remit of the pregnancy registers and the wider research focus has moved beyond anatomical major congenital malformations. Increasingly neurodevelopmental and behavioral abnormalities have been investigated after in utero exposure to antiseizure medications. Public health approaches can help reduce the risk of teratogenicity. However, neurologists still have a vital role in reducing the risk of teratogenicity at an individual level for women attending their clinic. They also have responsibility to ensure that women with epilepsy are aware of the rationale for the different available options.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Thieme Gruppe
ISSN:	0271-8235
Date of First Compliant Deposit:	23 April 2024
Date of Acceptance:	2022
Last Modified:	03 Sep 2024 09:45
URI:	https://orca.cardiff.ac.uk/id/eprint/168239

Actions (repository staff only)

Edit Item